Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday

Sagimet Biosciences (NASDAQ:SGMT) will likely be announcing its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 9:30 AM ET.

Sagimet Biosciences Stock Down 1.7%

Sagimet Biosciences stock opened at $5.62 on Wednesday. Sagimet Biosciences has a 52-week low of $1.73 and a 52-week high of $11.41. The firm has a market cap of $182.76 million, a PE ratio of -3.16 and a beta of 3.35. The company’s 50 day moving average is $5.81 and its two-hundred day moving average is $6.71.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Barclays began coverage on Sagimet Biosciences in a report on Tuesday, January 27th. They issued an “equal weight” rating and a $8.00 target price for the company. Citigroup reiterated an “outperform” rating on shares of Sagimet Biosciences in a research note on Friday, November 14th. Citizens Jmp boosted their price objective on Sagimet Biosciences from $33.00 to $35.00 and gave the stock a “market outperform” rating in a research report on Friday, November 14th. Wall Street Zen lowered shares of Sagimet Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Finally, Guggenheim assumed coverage on shares of Sagimet Biosciences in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $27.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $26.00.

Insiders Place Their Bets

In related news, CEO David Happel sold 12,101 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total value of $64,861.36. Following the completion of the transaction, the chief executive officer directly owned 677,621 shares of the company’s stock, valued at $3,632,048.56. This represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 14.70% of the stock is currently owned by insiders.

Institutional Trading of Sagimet Biosciences

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Sagimet Biosciences by 4.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,203,231 shares of the company’s stock valued at $8,254,000 after buying an additional 49,375 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Sagimet Biosciences by 228.1% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company’s stock worth $6,798,000 after purchasing an additional 798,245 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Sagimet Biosciences during the fourth quarter worth about $4,620,000. Millennium Management LLC lifted its holdings in shares of Sagimet Biosciences by 6,484.7% in the 3rd quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock valued at $5,326,000 after purchasing an additional 788,537 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its position in shares of Sagimet Biosciences by 462.4% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 523,774 shares of the company’s stock valued at $3,593,000 after purchasing an additional 430,644 shares during the period. Hedge funds and other institutional investors own 87.86% of the company’s stock.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.